November 23, 2014 -- Nanjing Frontier Biotechnologies gained global rights to a novel topical patch for acute and chronic pain management from ABsize Inc. of Japan. The product, AB001, has completed a Phase I trial in the US. AB001 is a prescription-strength NSAID topical patch to treat acute pain and inflammation of the joints and muscles. ABsize is a spin-off from Osaka University with a novel nanosizing process that allows patch delivery.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
